13 completed, 2 terminated, 2 unknown. 13 Phase 2, 3 Phase 1, 3 Phase 3.
By phase and status
Follow catumaxomab: new trials by email Literature Review of catumaxomab trials Research Report on catumaxomab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine Catumaxomab - Bladder Cancer Phase 1 / Phase 2 Unknown 161 2021-11-23 2023-02-13 Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis Catumaxomab, The treatment of investigator choice - Stomach Neoplasms Phase 3 Unknown 282 2020-10-06 2023-01-31 Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC Catumaxomab - Urinary Bladder Neoplasms Phase 1 Completed 34 2020-07-07 2026-10-16 Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer Catumaxomab - Recurrent Epithelial Ovarian Cancer Phase 2 Completed 2 2013-03-01 2015-02-18 Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab Catumaxomab 100µg, Catumaxomab 140µg - Patients With Gastric Peritoneal Carcinomatosis Phase 2 Terminated 26 2012-11-01 2017-01-26 Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel, Fluorouracil, leucovorin, oxaliplatin, docetaxel - Gastric Adenocarcinoma With Peritoneal Carcinomatosis, Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis Phase 2 Completed 42 2011-10-01 2018-01-23 A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients catumaxomab - Epithelial Cancer Patients Phase 1 Terminated 16 2011-02-01 2013-07-02 Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission Catumaxomab - Ovarian Cancer Phase 2 Completed 39 2010-06-01 2016-08-11 Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites catumaxomab - Malignant Ascites Due to Epithelial Carcinoma Phase 2 Completed 8 2009-11-01 2012-10-03 CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers Catumaxomab, Prednisolone - Cancer, Neoplasms Phase 3 Completed 230 2008-12-01 2012-10-03 Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer Catumaxomab - Ovarian Cancer, Epithelial Ovarian Cancer Phase 2 Completed 41 2007-11-01 2012-10-03 Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection Catumaxomab, catumaxomab - Gastric Cancer, Gastric Adenocarcinoma Phase 2 Completed 70 2007-04-01 2013-12-04 Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy catumaxomab - Ovarian Cancer Phase 2 Completed 47 2006-09-01 2012-07-19 Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma catumaxomab - Gastric Cancer, Gastric Adenocarcinoma Phase 2 Completed 40 2006-07-01 2007-10-26 Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites catumaxomab - Malignant Ascites Phase 2 Completed 32 2006-06-01 2018-10-17 Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group Catumaxomab (Removab), paracentesis - EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast), Malignant Ascites Phase 2 / Phase 3 Completed 258 2004-09-01 2009-02-05 Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients anti-EpCAM x anti-CD3 (removab) - Ovarian Cancer, Fallopian Tube Neoplasms Phase 2 Completed 44 2004-05-01 2006-11-08
Conditions studied Ovarian Neoplasms (5) · Carcinoma (4) · Carcinoma, Ovarian Epithelial (4) · Fallopian Tube Neoplasms (3) · Neoplasms (3) · Peritoneal Neoplasms (3) · Stomach Neoplasms (3) · Urinary Bladder Neoplasms (2) · Adenocarcinoma (1) · Ascites (1) · Neoplasms, Glandular and Epithelial (1) · Non-Muscle Invasive Bladder Neoplasms (1)
Sponsors Neovii Biotech (9) · LintonPharm Co.,Ltd. (2) · AGO Study Group (1) · AIO-Studien-gGmbH (1) · Grupo Español de Investigación en Cáncer de Ovario (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · JSehouli (1) · Lindis Biotech GmbH (1)
Countries Germany (9) · Spain (4) · Austria (3) · China (2) · France (2) · United States (2) · Denmark (1) · Italy (1) · South Korea (1) · Taiwan (1) · United Kingdom (1)
Top investigators Ana Herrero, Dra. (1) · Ana Oaknin, Dra. (1) · Ana Santaballa, Dra. (1) · Ana de Juan, Dra. (1) · Antonio Casado, Dr. (1) · Antonio Gonzalez, Dr. (1) · Arantxa Gonzalez, Dra. (1) · Carsten Bokemeyer, Prof MD (1) · Christian Dittrich, Prim.Univ.-Prof. (1) · Eva Guerra, Dra. (1) · Florian Lordick, PD Dr. med. (1) · Florian Lordick, Prof. Dr. (1)
Results publications PMID 21733566 , PMID 22734013 , PMID 25254563 , PMID 26049121
NIH funding 2009 (1) , 2019 (1)